Brief: Structure Therapeutics Reports Positive Topline Data From ACCESS Program For Its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics

08/12/2025 13:23

Dec 8 (Reuters) - Structure Therapeutics Inc GPCR.O:

STRUCTURE THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM ACCESS PROGRAM FOR ITS ONCE-DAILY ORAL SMALL MOLECULE GLP-1 RECEPTOR AGONIST, ALENIGLIPRON

STRUCTURE THERAPEUTICS INC - ALENIGLIPRON ACHIEVES 11.3% WEIGHT LOSS WITH 120 MG DOSE

STRUCTURE THERAPEUTICS INC - NO TREATMENT DISCONTINUATIONS AT LOWER 2.5 MG DOSE IN ACCESS PROGRAM

STRUCTURE THERAPEUTICS INC - ALENIGLIPRON TO ADVANCE TO PHASE 3 CLINICAL DEVELOPMENT

Source text: ID:nGNXVbFB

Further company coverage: GPCR.O

 ((Reuters.Briefs@thomsonreuters.com;))